Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

Phase 1/2 Active not recruiting 42 enrolled Immunophotonics, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.

Timeline

Start: 2022-11-29
Primary completion: 2025-02
Completion: 2025-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IP-001	Other / unclassified	1 %	Intrathecal
Subject	IP-001	Other / unclassified	4 ml	Intrathecal

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

Summary

Timeline

Drugs

Indications